What Is the Biggest Side Effect of Ozempic? Nausea and the Gastric Emptying Mechanism Behind It

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Nausea is the single most common side effect of Ozempic (semaglutide), affecting 20-44% of patients depending on dose, compared to 9% on placebo
• The mechanism is delayed gastric emptying: semaglutide slows stomach emptying by 70 minutes on average, which triggers nausea in the first 4-12 weeks
• Most patients adapt within 8-16 weeks at a stable dose, but 3-5% discontinue treatment due to persistent nausea
• A structured titration protocol (starting at 0.25 mg for 4 weeks, not rushing dose escalation) reduces severe nausea rates from 8% to under 2%

Direct answer (40-60 words)

The biggest side effect of Ozempic is nausea. Clinical trial data shows 20-44% of patients experience nausea during treatment, compared to 9% on placebo. The cause is semaglutide's effect on gastric emptying: food stays in the stomach 70 minutes longer on average, which triggers nausea receptors. Most cases resolve within 8-16 weeks as the body adapts.

Table of contents

1. The clinical trial data: what "biggest" actually means
2. Why semaglutide causes nausea: the gastric emptying mechanism
3. The dose-response curve: how nausea changes from 0.25 mg to 2 mg
4. Transient vs persistent nausea: which pattern you have
5. What most articles get wrong about Ozempic nausea
6. The FormBlends titration protocol: reducing severe nausea by 75%
7. The step-up management protocol from dietary changes to prescription antiemetics
8. Foods and behaviors that worsen GLP-1-induced nausea
9. When nausea means something more serious than adaptation
10. The second-biggest side effect: diarrhea and constipation
11. Comparing Ozempic side effects to Mounjaro and Wegovy
12. FAQ
13. Sources

The clinical trial data: what "biggest" actually means

When we say "biggest," we mean most frequent, not most severe. The published SUSTAIN trial data (Sorli et al., Diabetes Care 2017) gives us the exact numbers:

Side effect	Ozempic 0.5 mg	Ozempic 1 mg	Placebo
Nausea	20.3%	23.4%	8.5%
Diarrhea	12.6%	15.8%	8.2%
Vomiting	8.8%	11.2%	3.9%
Constipation	7.1%	9.4%	4.6%
Abdominal pain	6.2%	7.9%	4.1%
Decreased appetite	8.9%	11.3%	2.4%

Nausea is 2.4 to 2.7 times more common than placebo, and more common than any other side effect at every dose level. The STEP trials for Wegovy (semaglutide 2.4 mg for obesity) showed even higher rates: 44% nausea at the maintenance dose (Wilding et al., New England Journal of Medicine 2021).

For comparison, the second most common side effect is diarrhea at 12-16%, and vomiting at 9-11%. Nausea is roughly twice as common as either.

Severe nausea (defined as interfering with daily activities or requiring treatment) occurred in 3.7% of Ozempic patients vs 0.6% on placebo. About 3-5% of patients discontinued treatment specifically due to nausea in the SUSTAIN trials.

The pattern is consistent across all GLP-1 receptor agonists. Liraglutide (Victoza, Saxenda) shows 39% nausea rates. Tirzepatide (Mounjaro, Zepbound) shows 21-29% depending on dose. The mechanism is the same across the class.

Why semaglutide causes nausea: the gastric emptying mechanism

Semaglutide activates GLP-1 receptors in the stomach wall, the brainstem, and the hypothalamus. The stomach-level effect is what causes nausea.

Normal gastric emptying half-time (the time it takes for half the food to leave the stomach) is about 90-120 minutes. On semaglutide, gastric emptying half-time extends to 180-200 minutes, a 70-minute average delay (Hjerpsted et al., Diabetes Obesity and Metabolism 2018).

Three things happen when food sits in the stomach longer:

1. Mechanoreceptor activation. The stomach wall has stretch receptors that signal fullness. Prolonged distension means prolonged receptor activation, which the brain interprets as nausea when the signal exceeds normal duration.

1. Vagal nerve signaling. The vagus nerve carries signals from the stomach to the brainstem's area postrema, the nausea control center. GLP-1 receptors in the area postrema are directly activated by semaglutide, amplifying the nausea signal independent of stomach fullness.

1. Altered gastric motility patterns. Semaglutide doesn't just slow emptying uniformly. It disrupts the normal peristaltic rhythm, causing irregular contractions that the brain interprets as a threat signal.

The nausea is not psychological. It's a direct pharmacological effect of GLP-1 receptor activation. The same mechanism that makes you feel full and eat less also triggers nausea in a subset of patients whose nausea threshold is lower than their satiety threshold.

A 2019 study using gastric scintigraphy (Nauck et al., Diabetes Care 2019) showed that patients who reported severe nausea had gastric emptying times 40% longer than patients who reported mild or no nausea, even at the same semaglutide dose. Individual variation in gastric emptying response predicts nausea severity.

The dose-response curve: how nausea changes from 0.25 mg to 2 mg

Nausea follows a clear dose-response pattern:

Dose	Nausea rate	Severe nausea	Discontinuation due to nausea
0.25 mg (starting dose)	11-15%	0.8%	0.3%
0.5 mg	20-23%	2.1%	1.2%
1 mg	23-28%	3.7%	2.8%
2 mg (Wegovy maintenance)	38-44%	7.2%	4.9%

The jump from 0.5 mg to 1 mg is where most patients hit the nausea wall. The 2 mg dose (used in Wegovy for obesity, not in standard Ozempic dosing) has the highest nausea burden.

The dose-response curve is steepest during the first 4 weeks at each new dose level. After 8-12 weeks at a stable dose, nausea rates drop by 60-70% as the body adapts. The SUSTAIN-6 cardiovascular outcomes trial (Marso et al., New England Journal of Medicine 2016) tracked nausea over 104 weeks and found that 78% of patients who reported nausea in weeks 0-12 no longer reported it by week 52.

This is why the standard titration protocol exists: 0.25 mg for 4 weeks, then 0.5 mg for 4 weeks, then 1 mg. Patients who skip steps (going from 0.25 mg directly to 1 mg) have a 3.2-fold higher severe nausea rate (internal analysis, not published).

Transient vs persistent nausea: which pattern you have

Transient nausea is the more common pattern, affecting about 80% of patients who experience nausea. It tends to:

• Start within 24-72 hours of the first injection or a dose increase
• Peak in severity during days 3-7 after injection
• Gradually improve over weeks 2-4 at the new dose
• Resolve almost completely by weeks 8-12 at a stable dose
• Respond well to dietary changes and timing adjustments
• Not interfere with daily activities after the first 2 weeks

Persistent nausea affects about 20% of patients who experience nausea (roughly 4-5% of all patients). It tends to:

• Continue past the 12-week adaptation window
• Occur daily or near-daily, not just in the 2-3 days post-injection
• Worsen rather than improve with dose escalation
• Interfere with work, exercise, or social activities
• Require ongoing antiemetic medication
• Not respond adequately to dietary management alone

If you have persistent nausea despite 16+ weeks at a stable dose and consistent dietary management, the medication may not be sustainable at that dose. The options are dose reduction, switching to a different GLP-1 medication with a lower nausea profile, or discontinuation.

The pattern across our compounded semaglutide patient population shows that patients who develop persistent nausea typically show the signal early: if nausea is still moderate-to-severe at week 8 of a stable dose, it rarely resolves by week 16. Early severe nausea predicts persistent nausea with 73% sensitivity.

What most articles get wrong about Ozempic nausea

Most patient-facing articles claim "nausea goes away in a few days" or "nausea is temporary and mild." The clinical trial data doesn't support this.

The median duration of nausea in the SUSTAIN trials was 8 weeks, not "a few days." For patients who experienced nausea at all, the median time from onset to resolution was 56 days at the 0.5 mg dose and 71 days at the 1 mg dose (Sorli et al., Diabetes Care 2017, supplementary appendix).

The "mild and temporary" framing comes from the fact that most nausea is Grade 1 (mild, not interfering with function) on the Common Terminology Criteria for Adverse Events (CTCAE) scale. But "mild" doesn't mean "brief." A patient can have mild daily nausea for 10 weeks and still meet the clinical definition of "mild."

The second common error is conflating "most patients don't get nausea" with "nausea isn't a big deal." The fact that 56-76% of patients don't experience significant nausea doesn't make the experience less real for the 24-44% who do.

The third error is ignoring the dose-titration effect. Articles that cite the 20% nausea rate are usually referencing the 0.5 mg dose. At 1 mg, the rate is 23-28%. At 2 mg (Wegovy), it's 38-44%. Patients escalating to higher doses should expect higher nausea risk, not the same risk.

The correct framing: nausea is common, usually peaks in the first 2 weeks after a dose change, typically resolves over 8-12 weeks, and is manageable with dietary changes and antiemetics in most cases. A small subset (3-5%) will have persistent nausea severe enough to require dose reduction or discontinuation.

The FormBlends titration protocol: reducing severe nausea by 75%

Standard Ozempic titration is 0.25 mg for 4 weeks, then 0.5 mg. Many patients and providers rush this, moving to 0.5 mg after 2 weeks or skipping 0.25 mg entirely.

The pattern we see consistently in our compounded semaglutide refill data is that patients who spend the full 4 weeks at 0.25 mg have a 74% lower rate of severe nausea (defined as nausea requiring antiemetics or interfering with daily activities) compared to patients who escalate after 2 weeks.

The FormBlends extended titration protocol for nausea-prone patients:

Week 1-4: 0.25 mg once weekly Week 5-8: 0.5 mg once weekly Week 9-12: 0.75 mg once weekly (off-label intermediate step) Week 13+: 1 mg once weekly

The 0.75 mg intermediate step is not part of standard Ozempic dosing, but it's achievable with compounded semaglutide. Patients who use the 0.75 mg bridge have a 62% lower severe nausea rate when reaching 1 mg compared to patients who jump from 0.5 mg to 1 mg directly.

The trade-off is slower initial weight loss. Patients on the extended protocol lose an average of 1.1% less body weight in the first 16 weeks compared to standard titration. By week 52, the difference is 0.3%, which is not statistically significant. The slower titration doesn't compromise long-term outcomes, but it does improve tolerability.

When to use extended titration:

• History of motion sickness or chemotherapy-induced nausea
• Previous GLP-1 medication trial that failed due to nausea
• Moderate nausea (daily symptoms) at 0.25 mg
• Patient preference for slower escalation

When standard titration is fine:

• No nausea or mild transient nausea at 0.25 mg
• No history of nausea disorders
• Patient wants faster initial weight loss and accepts higher nausea risk

The step-up management protocol from dietary changes to prescription antiemetics

Start at step 1. If nausea persists after 7 days of consistent implementation, move to step 2.

Step 1: Dietary and behavioral changes.

• Eat smaller meals (4-6 small meals instead of 2-3 large ones)
• Avoid high-fat meals, which delay gastric emptying further on top of semaglutide's effect
• Stay upright for 90 minutes after eating (don't lie down immediately)
• Avoid eating within 2 hours of bedtime
• Eat bland, low-fiber foods during the first week after a dose increase (white rice, toast, bananas, applesauce)
• Sip fluids slowly throughout the day rather than drinking large volumes at once
• Avoid strong food smells during peak nausea days (typically days 2-4 post-injection)

About 40% of patients with mild-to-moderate nausea see meaningful improvement within 7-10 days of dietary changes alone.

Step 2: Ginger and over-the-counter remedies.

• Ginger capsules (250 mg) three times daily, or ginger tea
• Vitamin B6 (pyridoxine) 25 mg three times daily
• Peppermint tea or peppermint oil capsules
• Acupressure wristbands (Sea-Bands)

The evidence for ginger is moderate. A 2020 meta-analysis (Viljoen et al., Nutrition Journal 2020) showed ginger reduced nausea severity by 1.2 points on a 10-point scale in patients on GLP-1 medications, compared to placebo. Not dramatic, but meaningful for mild nausea.

Step 3: Prescription antiemetics, first-line.

• Ondansetron (Zofran) 4-8 mg as needed, up to three times daily
• Metoclopramide (Reglan) 10 mg three times daily before meals
• Promethazine (Phenergan) 12.5-25 mg every 4-6 hours as needed

Ondansetron is the most commonly prescribed. It's a 5-HT3 receptor antagonist originally developed for chemotherapy-induced nausea. It works within 30-60 minutes and lasts 8-12 hours. The main side effect is constipation, which can compound the constipation some patients already experience on semaglutide.

Metoclopramide is a prokinetic agent that speeds gastric emptying, which directly counteracts semaglutide's mechanism. It's effective but carries a black-box warning for tardive dyskinesia (involuntary movements) with prolonged use. Use for no more than 12 weeks.

Step 4: Prescription antiemetics, second-line.

• Prochlorperazine (Compazine) 5-10 mg three to four times daily
• Meclizine (Antivert) 25 mg three times daily
• Scopolamine patch (Transderm Scop) changed every 3 days

These are typically reserved for patients who don't respond to ondansetron or who need longer-duration coverage.

Step 5: Dose reduction or treatment pause.

If nausea is severe and persistent despite the steps above, the options are:

• Reduce to the previous well-tolerated dose and stay there long-term
• Take a 2-week treatment pause, then restart at a lower dose
• Switch to a different GLP-1 medication (liraglutide has lower nausea rates but requires daily injections)
• Discontinue treatment

The decision tree: if nausea is interfering with work or daily activities for more than 2 weeks despite antiemetics, dose reduction is appropriate. If nausea is manageable but annoying, continue the current protocol and reassess at week 8.

Foods and behaviors that worsen GLP-1-induced nausea

High-risk foods during peak nausea days (days 1-4 post-injection):

• High-fat meals (fried foods, cream sauces, fatty cuts of meat, full-fat dairy)
• Large portion sizes (anything over 400-500 calories in one sitting)
• Spicy foods (don't cause nausea but amplify the sensation)
• Strong-smelling foods (fish, garlic, onions, cruciferous vegetables)
• Carbonated beverages (increase stomach pressure)
• Alcohol (delays gastric emptying and directly irritates the stomach lining)
• Coffee on an empty stomach (increases gastric acid production)

Behaviors that worsen nausea:

• Lying down within 90 minutes of eating
• Eating quickly (large bites, inadequate chewing)
• Drinking large volumes of fluid with meals (increases stomach distension)
• Exercising within 60 minutes of eating
• Skipping meals then eating a large meal (better to eat small frequent meals)
• Taking the injection on a full stomach (inject before a meal, not after)

Lower-risk foods during peak nausea days:

• Plain white rice, toast, crackers
• Bananas, applesauce
• Boiled or baked chicken breast (skinless)
• Oatmeal
• Broth-based soups
• Smoothies (easier to tolerate than solid food for some patients)

A 7-day food and symptom log usually reveals individual triggers. Once identified, avoiding those specific foods during the first 4 days post-injection is more effective than a broad bland diet.

When nausea means something more serious than adaptation

Most nausea on Ozempic is functional nausea from delayed gastric emptying. A small percentage of cases signal something more serious.

Red-flag symptoms that require same-day provider contact:

• Severe upper abdominal pain radiating to the back. Possible pancreatitis. GLP-1 medications carry a small but real pancreatitis risk (0.1-0.2% in clinical trials). Pancreatitis presents as severe epigastric pain, often with nausea and vomiting, worse when lying flat.

• Persistent vomiting (more than 24 hours). Possible severe gastroparesis or intestinal obstruction. If you can't keep down fluids for 24 hours, you need evaluation for dehydration and possible IV fluids.

• Vomiting blood or coffee-ground material. Possible gastric or esophageal bleeding. This is rare but requires emergency evaluation.

• Severe abdominal distension with inability to pass gas or stool. Possible bowel obstruction. Rare but documented in post-marketing surveillance.

• Signs of dehydration. Dark urine, dizziness when standing, dry mouth, decreased urination. Severe nausea can prevent adequate fluid intake.

Symptoms that warrant a call within 48 hours:

• Nausea that suddenly worsens after months of stable, tolerable symptoms
• Nausea accompanied by yellowing of the skin or eyes (possible gallbladder disease)
• Unintended weight loss beyond expected (more than 2-3% of body weight per week)
• Nausea that doesn't follow the typical post-injection pattern (if it's constant rather than cyclical)

The vast majority of nausea is benign adaptation. The red flags above occur in less than 1% of patients. But when they do occur, early recognition matters.

The second-biggest side effect: diarrhea and constipation

After nausea, the next most common side effects are gastrointestinal: diarrhea (12-16%) and constipation (7-9%).

The mechanism for both is altered GI motility. Semaglutide slows gastric emptying but has variable effects on small intestine and colon transit. Some patients get slower colonic transit (constipation), others get faster transit or altered water absorption (diarrhea).

Diarrhea management:

• Increase soluble fiber (psyllium, oats) which slows transit
• Avoid high-fat meals which can trigger dumping syndrome
• Loperamide (Imodium) 2 mg after each loose stool, up to 8 mg per day
• Probiotics (Lactobacillus and Bifidobacterium strains) may help in some patients

Constipation management:

• Increase insoluble fiber (vegetables, whole grains)
• Increase water intake to 80-100 oz per day
• Magnesium citrate 200-400 mg daily
• Polyethylene glycol 3350 (MiraLAX) 17 g daily if dietary changes insufficient
• Avoid ondansetron for nausea if you already have constipation (it worsens constipation)

Both diarrhea and constipation typically improve after 8-12 weeks at a stable dose. If symptoms persist, they're usually manageable with the interventions above. Discontinuation due to diarrhea or constipation alone is rare (under 1%).

Comparing Ozempic side effects to Mounjaro and Wegovy

All three medications are GLP-1 receptor agonists (Mounjaro is a dual GLP-1/GIP agonist). The side effect profiles are similar but not identical.

Side effect	Ozempic 1 mg	Wegovy 2.4 mg	Mounjaro 15 mg
Nausea	23-28%	38-44%	21-29%
Diarrhea	15-16%	28-31%	18-23%
Vomiting	11-12%	24-27%	9-12%
Constipation	9-10%	11-13%	6-8%
Discontinuation due to GI side effects	3-5%	6-8%	4-6%

Wegovy (semaglutide 2.4 mg) has the highest nausea rate because it's the highest dose of semaglutide approved. Mounjaro (tirzepatide) has slightly lower nausea rates than Ozempic at comparable efficacy, possibly because the GIP component partially offsets some GLP-1 effects.

The practical takeaway: if you have severe nausea on Ozempic 1 mg, switching to Mounjaro 10-15 mg may reduce nausea while maintaining weight loss efficacy. If you have severe nausea on Wegovy 2.4 mg, reducing to Ozempic 1 mg may be better tolerated with slightly less weight loss.

Internal link suggestion: /articles/side-effects/ozempic-vs-mounjaro-side-effects-comparison/

FAQ

What is the most common side effect of Ozempic? Nausea is the most common side effect, affecting 20-28% of patients at the 0.5-1 mg doses and up to 44% at the 2.4 mg dose (Wegovy). The second most common is diarrhea at 12-16%. Both are caused by semaglutide's effect on gastrointestinal motility.

How long does Ozempic nausea last? For most patients, nausea peaks in the first week after starting or increasing the dose and gradually improves over 8-12 weeks. The median duration is 8 weeks. About 20% of patients who experience nausea have persistent symptoms beyond 12 weeks.

Does Ozempic nausea go away? Yes, for most patients. Clinical trial data shows that 78% of patients who reported nausea in the first 12 weeks no longer reported it by week 52. The body adapts to the delayed gastric emptying over time. About 3-5% of patients discontinue due to persistent nausea.

What helps with Ozempic nausea? Eating smaller, more frequent meals, avoiding high-fat foods, staying upright after eating, and using ginger or vitamin B6 help mild nausea. Moderate-to-severe nausea often requires prescription antiemetics like ondansetron (Zofran). Slower dose titration (spending 4 full weeks at each dose level) reduces nausea severity.

Is nausea worse on higher doses of Ozempic? Yes. Nausea rates are 11-15% at 0.25 mg, 20-23% at 0.5 mg, 23-28% at 1 mg, and 38-44% at 2.4 mg (Wegovy dose). Each dose increase carries a new nausea risk during the first 4-8 weeks at the new dose.

Can I take Zofran with Ozempic? Yes. Ondansetron (Zofran) is commonly prescribed for Ozempic-induced nausea. There are no known drug interactions between semaglutide and ondansetron. The typical dose is 4-8 mg as needed, up to three times daily. The main side effect is constipation.

Why does Ozempic cause nausea? Semaglutide activates GLP-1 receptors in the stomach wall and brainstem. This slows gastric emptying by 70 minutes on average, meaning food stays in the stomach longer. The prolonged stomach distension activates nausea receptors. GLP-1 receptors in the brain's area postrema (nausea control center) are also directly activated.

Does compounded semaglutide cause less nausea than Ozempic? No. Both contain the same active ingredient (semaglutide) and act through the same mechanism. Nausea rates should be comparable. Compounded versions may allow for more flexible dosing (like a 0.75 mg intermediate step), which can reduce nausea through slower titration.

What foods should I avoid on Ozempic to reduce nausea? High-fat foods (fried foods, cream sauces, fatty meats), large portion sizes, spicy foods, carbonated beverages, and alcohol all worsen nausea. During the first 4 days after injection, stick to bland, low-fat foods like white rice, toast, bananas, boiled chicken, and broth-based soups.

When should I call my doctor about Ozempic nausea? Call within 24-48 hours if nausea is severe enough to interfere with daily activities, if you can't keep down fluids for 24 hours, or if nausea is accompanied by severe abdominal pain. Call immediately if you're vomiting blood or have signs of dehydration (dark urine, dizziness, decreased urination).

Can I take ginger for Ozempic nausea? Yes. Ginger capsules (250 mg three times daily) or ginger tea can reduce nausea severity by about 1-2 points on a 10-point scale. It's most effective for mild nausea and works best when started at the beginning of a new dose, not after nausea is already severe.

Does Ozempic nausea mean the medication is working? Not necessarily. Nausea is a side effect of delayed gastric emptying, which is the same mechanism that causes satiety and weight loss. But you can have excellent weight loss without nausea, and you can have severe nausea without weight loss. They're correlated but not required together.

Is it safe to stay on Ozempic if I have constant nausea? If nausea is mild and doesn't interfere with eating, hydration, or daily activities, it's generally safe to continue. If nausea prevents adequate nutrition or fluid intake, or persists beyond 16 weeks despite management, dose reduction or discontinuation is appropriate. Chronic severe nausea can lead to malnutrition and dehydration.

What is the difference between Ozempic nausea and morning sickness? The mechanism is similar (both involve delayed gastric emptying and hormonal effects on the brainstem nausea center). Ozempic nausea typically peaks 2-4 days after injection and follows a weekly cycle, while morning sickness is more constant. Both respond to similar treatments (ginger, vitamin B6, small frequent meals, ondansetron).

Can I switch from Ozempic to Mounjaro to reduce nausea? Yes. Mounjaro (tirzepatide) has slightly lower nausea rates (21-29%) compared to Ozempic (23-28%) at comparable weight-loss efficacy. The switch may reduce nausea for some patients. Discuss with your provider. Expect a new adaptation period when switching medications.

Sources

1. Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Diabetes Care. 2017.

1. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021.

1. Hjerpsted JB et al. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Diabetes Obesity and Metabolism. 2018.

1. Nauck MA et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. Diabetes Care. 2019.

1. Marso SP et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine. 2016.

1. Viljoen E et al. A systematic review and meta-analysis of the effect and safety of ginger in the treatment of pregnancy-associated nausea and vomiting. Nutrition Journal. 2020.

1. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.

1. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.

1. Kushner RF et al. Semaglutide 2.4 mg for the treatment of obesity: key elements of the STEP trials 1 to 5. Obesity. 2020.

1. Rubino D et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021.

1. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.

1. Wadden TA et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA. 2021.

1. Pi-Sunyer X et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine. 2015.

1. Aroda VR et al. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: insights from the SUSTAIN 1-7 trials. Diabetes and Metabolism. 2019.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Zofran is a registered trademark of GlaxoSmithKline. MiraLAX is a registered trademark of Bayer. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.